This randomized, double-blind, multicenter study evaluated a single transendocardial administration procedure of mesenchymal precursor cellss or sham-control in 565 intention-to-treat patients with heart failure with reduced ejection fraction on guideline-directed therapies.
[Journal Of The American College Of Cardiology]